Ovid Therapeutics Raises $81M to Advance Epilepsy Treatments

Ovid Therapeutics, a biopharmaceutical company striving to calm the storm that causes seizures by developing new medicines for epilepsies and brain conditions, has announced it has secured $81,000,000 in new funding. This significant investment will enable the company to further its mission of bringing relief to patients. The company is dedicated to pursuing small molecule compounds with untapped potential. Ovid Therapeutics applies a nimble and proven approach to accelerate clinical development, aiming to translate its molecules into first-in-class or best-in-class medicines. Their strategy involves close collaboration with patient, clinician, and academic communities throughout the development process, from bench to bedside. The accomplished team at Ovid has a track record of success in making medicines for rare diseases and neurology, driven by a bold goal for the communities they serve. This funding round underscores investor confidence in Ovid Therapeutics' scientific platform and drug development pipeline. The capital is expected to primarily support the advancement of its ongoing research and development initiatives, particularly in its portfolio of small molecule compounds for epilepsies and other brain conditions. Ovid Therapeutics plans to utilize these funds to expand its clinical programs, bolster operational capabilities, and accelerate the progression of potential therapies. Looking ahead, Ovid Therapeutics remains committed to its aspiration of a future free of seizures. The company intends to leverage this investment to continue its urgent, ingenious, and integrity-driven pursuit of novel treatments, strengthening its position in neurological medicine and working towards its goal of delivering impactful solutions to those in need.